Compassionate Use of the Incraft® AAA Stent Graft System
Primary Purpose
Abdominal Aortic Aneurysm
Status
No longer available
Phase
Locations
United States
Study Type
Expanded Access
Intervention
Endovascular AAA repair
Sponsored by
About this trial
This is an expanded access trial for Abdominal Aortic Aneurysm focused on measuring Abdominal Aortic Aneurysm
Eligibility Criteria
- Obtain an independent assessment by an uninvolved physician.
- Obtain informed consent from the patient or legal representative. The consent form used should provide information pertinent to the patient's specific situation. (If appropriate, the study consent form may be used with an addendum to inform the patient of concerns specific to their situation.)
- Obtain clearance from the institution in accordance with their policies.
- Notify the institutional review board and comply with their procedures.
Sites / Locations
- Cordis Corporation
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01776450
Brief Title
Compassionate Use of the Incraft® AAA Stent Graft System
Official Title
Compassionate Use of the Incraft® AAA Stent Graft System
Study Type
Expanded Access
2. Study Status
Record Verification Date
July 2019
Overall Recruitment Status
No longer available
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cordis Corporation
4. Oversight
5. Study Description
Brief Summary
To treat patients with abdominal aortic aneurysms requiring endovascular repair outside of the clinical protocol through compassionate use.
Detailed Description
In the US, abdominal aortic aneurysms (AAA) are found in 4-8% of older men and 0.5-1.5% of older women, resulting in 30,000-40,000 elective procedures and 1,400 peri-operative deaths. The most significant complication of AAA is an aneurysm sac rupture from which more than 15,000 patients die annually and is the 15th leading cause of death in elderly between 60 to 85 years of age . In Japan, it is estimated that approximately 14,000 endovascular aneurysm repair (EVAR) and open surgical repair cases were performed in the year 2010 .
Abdominal aortic aneurysms can be treated three ways: (1) Medical management; (2) Open surgical repair; and (3) Endovascular aneurysm repair (EVAR). EVAR has emerged as an alternative treatment of AAA for most patients. It is less invasive than open repair and carries lower rates of early mortality and morbidity . It has also extended treatment options to patients who cannot undergo conventional surgical procedures due to a high operative risk. As EVAR technology evolves, it allows treatment of AAA with increasing complexity of the aortic neck and access vessels.
The InCraft ®AAA Stent Graft System is designed for endovascular repair of infrarenal AAAs with complex aortic anatomies. This stent-graft system utilizes nitinol stent and polyester graft technology in an ultra-low profile delivery system, which assists the physician in deploying the device in a controlled, consistent, and precise manner within the aortic neck and iliac arteries. By isolating the aneurysmal sac, the system provides an alternative blood flow path to relieve pressure on the arterial vessel walls and minimize aneurysm growth and the potential for aneurysm sac rupture.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abdominal Aortic Aneurysm
Keywords
Abdominal Aortic Aneurysm
7. Study Design
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
Endovascular AAA repair
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Obtain an independent assessment by an uninvolved physician.
Obtain informed consent from the patient or legal representative. The consent form used should provide information pertinent to the patient's specific situation. (If appropriate, the study consent form may be used with an addendum to inform the patient of concerns specific to their situation.)
Obtain clearance from the institution in accordance with their policies.
Notify the institutional review board and comply with their procedures.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michel S Makaroun, MD
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Takao Ohki, MD
Organizational Affiliation
Jikei University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cordis Corporation
City
Fremont
State/Province
California
ZIP/Postal Code
94555
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Compassionate Use of the Incraft® AAA Stent Graft System
We'll reach out to this number within 24 hrs